| Schedule of details of and movement in goodwill |
Details of and movement in this caption of the consolidated balance sheet at 31 December 2025 are as follows: | | | | | | | | | | | | | | | | | Millions of Euros | | | | | Balance at | | Business | | | | Translation | | Balance at | | | Segment | | 31/12/2024 | | Combination | | Impairment | | differences | | 31/12/2025 | Net value | | | | | | | | | | | | | Grifols UK, Ltd. (UK) | | Biopharma | | 8 | | — | | — | | — | | 8 | Grifols Italia.S.p.A. (Italy) | | Biopharma | | 6 | | — | | — | | — | | 6 | Biomat USA, Inc. (USA) | | Biopharma | | 912 | | — | | — | | (106) | | 806 | Grifols Australia Pty Ltd. (Australia) / Medion Diagnostics AG (Switzerland) | | Diagnostic | | 10 | | — | | — | | — | | 10 | Grifols Therapeutics, Inc. (USA) | | Biopharma | | 2,139 | | — | | — | | (248) | | 1,891 | Progenika Biopharma, S.A. (Spain) | | Diagnostic | | 41 | | — | | — | | — | | 41 | Grifols Diagnostic (Novartis & Hologic) (USA, Spain and Hong Kong) | | Diagnostic | | 2,795 | | — | | — | | (321) | | 2,474 | Kiro Grifols, S.L. (Spain) | | Others | | 15 | | — | | — | | — | | 15 | Haema, GmbH. (Germany) | | Biopharma | | 190 | | — | | — | | — | | 190 | BPC Plasma, Inc. (USA) | | Biopharma | | 165 | | — | | — | | (19) | | 146 | Plasmavita Healthcare GmbH (Germany) | | Biopharma | | 10 | | — | | — | | — | | 10 | Alkahest, Inc (USA) | | Others | | 85 | | — | | (10) | | (10) | | 65 | Grifols Canada Therapeutics, Inc (Canada) | | Biopharma | | 150 | | — | | — | | (11) | | 139 | GigaGen, Inc (USA) | | Others | | 123 | | — | | — | | (14) | | 109 | Haema Plasma Kft. (Hungary) | | Biopharma | | 13 | | — | | — | | 1 | | 14 | Grifols Canada Plasma II. (formerly Grifols Canada Plasma Inc.) (Canada) | | Biopharma | | 10 | | — | | — | | (1) | | 9 | Grifols Biotest Holdings GmbH / Biotest AG (Germany) | | Biopharma | | 304 | | — | | — | | — | | 304 | Grifols Bio Supplies Inc (USA) | | Bio Supplies | | 184 | | — | | — | | (21) | | 163 | Biomat Holdings LLC (USA) | | Biopharma | | 243 | | 244 | | — | | (54) | | 433 | | | | | 7,403 | | 244 | | (10) | | (804) | | 6,833 | | | | | | | (See Note 3) | | | | | | |
Details of and movement in this caption of the consolidated balance sheet at 31 December 2024 were as follows: | | | | | | | | | | | | | | | | | | | Millions of Euros | | | | | Balance at | | Business | | | | | | Translation | | Balance at | | | Segment | | 31/12/2023 | | Combination | | Disposals | | Impairment | | differences | | 31/12/2024 | Net value | | | | | | | | | | | | | | | Grifols UK, Ltd. (UK) | | Biopharma | | 8 | | — | | — | | — | | — | | 8 | Grifols Italia.S.p.A. (Italy) | | Biopharma | | 6 | | — | | — | | — | | — | | 6 | Biomat USA, Inc. (USA) | | Biopharma | | 869 | | — | | (11) | | — | | 54 | | 912 | Grifols Australia Pty Ltd. (Australia) / Medion Diagnostics AG (Switzerland) | | Diagnostic | | 10 | | — | | — | | — | | — | | 10 | Grifols Therapeutics, Inc. (USA) | | Biopharma | | 2,011 | | — | | — | | — | | 128 | | 2,139 | Progenika Biopharma, S.A. (Spain) | | Diagnostic | | 41 | | — | | — | | — | | — | | 41 | Grifols Diagnostic (Novartis & Hologic) (USA, Spain and Hong Kong) | | Diagnostic | | 2,629 | | — | | — | | — | | 166 | | 2,795 | Kiro Grifols, S.L. (Spain) | | Others | | 24 | | — | | — | | (9) | | — | | 15 | Haema, GmbH. (Germany) | | Biopharma | | 190 | | — | | — | | — | | — | | 190 | BPC Plasma, Inc. (USA) | | Biopharma | | 155 | | — | | — | | — | | 10 | | 165 | Plasmavita Healthcare GmbH (Germany) | | Biopharma | | 10 | | — | | — | | — | | — | | 10 | Alkahest, Inc (USA) | | Others | | 80 | | — | | — | | — | | 5 | | 85 | Grifols Canada Therapeutics, Inc (Canada) | | Biopharma | | 153 | | — | | — | | — | | (3) | | 150 | GigaGen, Inc (USA) | | Others | | 115 | | — | | — | | — | | 8 | | 123 | Haema Plasma Kft. (Hungary) | | Biopharma | | 14 | | — | | — | | — | | (1) | | 13 | Grifols Canada Plasma II. (formerly Grifols Canada Plasma Inc.) (Canada) | | Biopharma | | 10 | | — | | — | | — | | — | | 10 | Grifols Biotest Holdings GmbH / Biotest AG (Germany) | | Biopharma | | 304 | | — | | — | | — | | — | | 304 | Grifols Bio Supplies Inc (USA) | | Bio Supplies | | 173 | | — | | — | | — | | 11 | | 184 | Biomat Holdings LLC (EEUU) | | Biopharma | | — | | 233 | | — | | — | | 10 | | 243 | | | | | 6,802 | | 233 | | (11) | | (9) | | 388 | | 7,403 | | | | | | | (see Note 3) | | | | | | | | |
|
| Schedule of key assumptions used for impairment testing, cash-generating units |
The key assumptions used in calculating impairment testing of the CGUs for 2025 have been as follows: | | | | | | | | Perpetual Growth rate | | Pre-tax discount rate | | Biopharma | | 2.0 | % | 11.2 | % | Diagnostic | | 2.0 | % | 11.2 | % | Bio Supplies | | 1.9 | % | 10.3 | % | Kiro Grifols | | 1.6 | % | 11.8 | % | GigaGen | | N/A | | 17.9 | % | Alkahest | | N/A | | 25.9% - 39.8 | % |
| | | | | | Success rate | | GigaGen | | 20.0 | % | Alkahest | | 12.0 | % |
| | | | | | | | | | | | CAGR | | CAGR | | CAGR | | CAGR | | | | sales | | sales | | EBITDA | | EBITDA | | | | 2025-2030 | | 2030-2034 | | 2025-2030 | | 2030-2034 | | Diagnostic | | 5 | % | 10 | % | 15 | % | 16 | % |
The key assumptions used in calculating impairment testing of the CGUs for 2024 were as follows: | | | | | | | | Perpetual Growth rate | | Pre-tax discount rate | | | | | | | | Biopharma | | 2.1 | % | 11.4 | % | Diagnostic | | 2.0 | % | 10.6 | % | Bio Supplies | | 1.9 | % | 10.6 | % | Kiro Grifols | | 1.6 | % | 11.6 | % | GigaGen | | NA | | 17.9 | % | Alkahest | | NA | | 25.9% - 39.8 | % |
| | | | | | | | Sink rate | | Success rate | | GigaGen | | 5.0 | % | 20.0 | % | Alkahest | | NA | | 12.0% - 17.0 | % |
| | | | | | | | | | | | CAGR | | CAGR | | CAGR | | CAGR | | | | sales | | sales | | EBITDA | | EBITDA | | | | 2024-2029 | | 2029-2034 | | 2024-2029 | | 2029-2034 | | Diagnostic | | 5 | % | 9 | % | 10 | % | 15 | % |
|
| Schedule of sensitivity analysis for impairment testing cash-generating units |
| | | | | | | Perpetual Growth rate | | Pre-tax discount rate | Biopharma | | +/- 50 bps | | +/- 50 bps | Diagnostic | | +/- 50 bps | | +/- 100 bps | Bio Supplies | | +/- 50 bps | | +/- 50 bps | Kiro Grifols | | +/- 50 bps | | +/- 50 bps | GigaGen | | N/A | | +/- 200 bps | Alkahest | | N/A | | +/- 200 bps |
| | | | | | % Potential Impairment over Asset Value | | | | | | Discount rate sensitivity Kiro +50bps | | -4 | % | Perpetual growth rate sensitivity Kiro -50bps | | -2 | % | Discount rate sensitivity GigaGen +200 bps | | -13 | % | Aggregate sensitivity scenario to MDS, BTS and CDx sales | | -11 | % | Discount rate sensitivity Alkahest +200bps | | -11 | % |
| | | | | | Kiro Grifols | | | | | | Amount by which the recoverable amount exceeds the carrying amount | | 2.0 | % | Pre-tax discount rate | | 11.8 | % | Perpetual growth rate | | 1.6 | % | Pre-tax discount rate at which the recoverable equals the carrying amount | | 12.0 | % | Perpetual growth rate at which the recoverable equals the carrying amount | | 1.4 | % |
| | | | | | GigaGen | | | | | | Amount by which the recoverable amount exceeds the carrying amount | | 12.0 | % | Pre-tax discount rate | | 17.9 | % | Pre-tax discount rate at which the recoverable equals the carrying amount | | 18.8 | % |
| | | | | | Diagnostic | | | | | | Amount by which the recoverable amount exceeds the carrying amount | | 14.0 | % | Sales and EBITDA CAGR (2025-2034) | | 7.7% / 15.3 | % | Sales and EBITDA CAGR (2025-2034) at which the recoverable amount equals the carrying amount | | 6.6% / 13.5 | % |
| | | | | | Alkahest | | | | | | Amount by which the recoverable amount exceeds the carrying amount | | 15.0 | % | Pre-tax discount rate | | 26% - 40 | % | Pre-tax discount rate at which the recoverable equals the carrying amount | | 27% - 41 | % |
In 2024, the reasonably possible changes considered for the CGUs impairment testing were a variation in the discount rate, as well as in the estimated perpetual growth rate, with independent movements of each other, as follows: | | | | | | | Perpetual Growth rate | | Pre-tax discount rate | Biopharma | | +/- 50 bps | | +/- 50 bps | Diagnostic | | +/- 50 bps | | +/- 100 bps | Bio Supplies | | +/- 50 bps | | +/- 50 bps | Kiro Grifols | | +/- 50 bps | | +/- 50 bps | GigaGen | | N/A | | +/- 200 bps | Alkahest | | N/A | | +/- 200 bps |
| | | | | Sink rate | GigaGen | | +/- 100 bps |
| | | | | | % Potential Impairment over Asset Value | | Discount rate sensitivity Kiro +50bps | | -5 | % | Perpetual growth rate sensitivity Kiro -50bps | | -4 | % | Discount rate sensitivity GigaGen +200 bps | | -7 | % | Aggregate sensitivity scenario to MDS, BTS and CDx sales | | -10 | % | Discount rate sensitivity Alkahest +200bps | | -17 | % |
| | | | | | Kiro Grifols | | | | | | Amount by which the recoverable amount exceeds the carrying amount | | — | % | Pre-tax discount rate | | 11.6 | % | Perpetual growth rate | | 1.6 | % | Pre-tax discount rate at which the recoverable equals the carrying amount | | 11.6 | % | Perpetual growth rate at which the recoverable equals the carrying amount | | 1.6 | % |
| | | | | | GigaGen | | | | | | Amount by which the recoverable amount exceeds the carrying amount | | 18.2 | % | Pre-tax discount rate | | 17.9 | % | Pre-tax discount rate at which the recoverable equals the carrying amount | | 19.3 | % |
| | | | | | Diagnostic | | | | | | Amount by which the recoverable amount exceeds the carrying amount | | 15.8 | % | Sales and EBITDA CAGR (2024-2034) | | 7.2% / 12.8 | % | Sales and EBITDA CAGR (2024-2034) at which the recoverable amount equals the carrying amount | | 6.0% / 10.7 | % |
| | | | | | Alkahest | | | | | | Amount by which the recoverable amount exceeds the carrying amount | | 9.3 | % | Pre-tax discount rate | | 26% - 40 | % | Pre-tax discount rate at which the recoverable equals the carrying amount | | 27% - 41 | % |
|